Frontiers Media

Bellabeat Unveils Next-Gen IVY Health Tracker for Women: A Leap Forward in Advanced Temperature Tracking and Wellness

Retrieved on: 
Tuesday, March 19, 2024
Research, Temperature, Health, Medicine, Frontiers Media, Menstrual cycle, IVY, Heart rate, Ovulation, Journal, Fertility, Pregnancy, Woman, Reproductive biology, Skin temperature, Machine learning, Menstruation, Map, Endocrinology, Birth control

San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.

Key Points: 
  • San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.
  • It is equipped with a sophisticated temperature tracking feature, marking a significant advancement in menstrual and fertility tracking.
  • In conjunction with the Bellabeat app, the IVY+ Health Tracker transforms biometric data into actionable wellness insights.
  • The combination of the IVY+ Health Tracker and the Bellabeat app creates a comprehensive health monitoring experience that extends beyond traditional tracking methods.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, March 29, 2024
Patient, PTCL, G&A, IND, Prednisone, Neoplasm, Therapy, SMDC, Medicinal chemistry, Lymphoma, Research, Frontiers Media, RNA polymerase II, Body modification, Primate, RNA, NIH, CPT, Potential, Safety, CDK9, ADC, MCL1, Solubility, Oncogene, RNA polymerase, Venetoclax, Journal, Manuscript, Cancer, Peripheral T-cell lymphoma, AACR, Antibody, MYC, Downregulation and upregulation, DLBCL, Annual general meeting, HER2, European Hematology Association, EHA, Spacecraft, PDX, Bangladesh Technical Education Board, Journal of Medicinal Chemistry, Blood, Pharmaceutical industry

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

ImpriMed to Present Innovative Research at 2024 World Veterinary Cancer Congress

Retrieved on: 
Wednesday, March 20, 2024
Pharmaceutical, Data Management, Oncology, Consumer, Technology, Medical Devices, Artificial Intelligence, Health Technology, Clinical Trials, Veterinary, Biotechnology, Health, Pets, B-cell lymphoma, Congress, Flow cytometry, Intelligence, Patient, Survival, RBCL, AI, Medicine, Lymphoma, Trial of the century, WVCC, Frontiers Media

WVCC -- ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the company’s participation at the upcoming World Veterinary Cancer Congress (WVCC) 2024 in Tokyo, Japan, from March 21-24, 2024.

Key Points: 
  • WVCC -- ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the company’s participation at the upcoming World Veterinary Cancer Congress (WVCC) 2024 in Tokyo, Japan, from March 21-24, 2024.
  • Lim’s presentation will summarize the remarkable results of an ImpriMed study published in Frontiers in Oncology that validate the efficacy of AI-driven drug response predictions in treating canine lymphoma.
  • These results, highlighted by Lim’s presentation, demonstrate AI’s powerful application in producing improved clinical outcomes and revolutionizing veterinary oncology.
  • "We are honored to advocate for AI’s transformative power by sharing our latest findings at the World Veterinary Cancer Congress," said Lim.

Best Life Insurance Plans for Multiple Sclerosis (MS) Patients - Our Top Picks for 2024

Retrieved on: 
Tuesday, March 12, 2024
Survival, ICC, Patient, History, SBLI, Legal & General, Research, Risk, Policy, Lincoln National Corporation, AEGON, Privacy, Hypertension, Disability, Database, Frontiers Media, Journal, Prescription, Neurosurgery, Roger Hawkins (drummer), MD, Insurance, Diagnosis, Psychiatry, Incidence, Prudential Financial, Mortality, Multiple sclerosis, Mutual, Corebridge Financial, Comorbidity, John Hancock Financial, Pharmaceutical industry

Michelle Zieba, Vice President of Sales, described the life insurance application process, "After receiving initial quotes, our MS customers will then be advised by our life insurance experts as to which plan is best.

Key Points: 
  • Michelle Zieba, Vice President of Sales, described the life insurance application process, "After receiving initial quotes, our MS customers will then be advised by our life insurance experts as to which plan is best.
  • A small number of people with Multiple Sclerosis experience very mild symptoms and little to no disability.
  • Zieba offered this advice to those with MS who are shopping for life insurance, "MS patients can do a lot to prepare to buy life insurance.
  • Instant life insurance quotes for those with Multiple Sclerosis of all severities are available at www.lifequotes.com .

Ruavieja brings you another moving Christmas campaign

Retrieved on: 
Thursday, November 30, 2023
Frontiers Media, Advertising, Collection, University, University of Louisville, Ageing, Projection, Life, Film industry

MADRID, Nov. 30, 2023 /PRNewswire/ -- Leading Galician liqueur brand Ruavieja has launched "The movie of your life," its Christmas campaign designed by TBWA\Spain, the creative agency led by Juan García-Escudero. The project, which is inspired by a scientific discovery made by neurosurgeon Ajmal Zemmar, aims to encourage people to reflect on life and the importance of all those moments that together make up each person's story.

Key Points: 
  • MADRID, Nov. 30, 2023 /PRNewswire/ -- Leading Galician liqueur brand Ruavieja has launched " The movie of your life ," its Christmas campaign designed by TBWA\Spain, the creative agency led by Juan García-Escudero.
  • Ruavieja has used this finding to create its Christmas campaign, which has a powerful message: a person's story is made up of shared moments that will be remembered at the very end.
  • Ruavieja then captured the moment when they watched the film, as well as their reactions, reminding us of the importance of spending time with the people we love.
  • The campaign takes the spirit of the iconic 2018 " We have to see more of each other " campaign and ends with the same slogan, reminding us to prioritise what really matters in life.

Ruavieja brings you another moving Christmas campaign

Retrieved on: 
Thursday, November 30, 2023
Frontiers Media, Advertising, Collection, University, University of Louisville, Ageing, Projection, Life, Film industry

MADRID, Nov. 30, 2023 /PRNewswire/ -- Leading Galician liqueur brand Ruavieja has launched "The movie of your life," its Christmas campaign designed by TBWA\Spain, the creative agency led by Juan García-Escudero. The project, which is inspired by a scientific discovery made by neurosurgeon Ajmal Zemmar, aims to encourage people to reflect on life and the importance of all those moments that together make up each person's story.

Key Points: 
  • MADRID, Nov. 30, 2023 /PRNewswire/ -- Leading Galician liqueur brand Ruavieja has launched " The movie of your life ," its Christmas campaign designed by TBWA\Spain, the creative agency led by Juan García-Escudero.
  • Ruavieja has used this finding to create its Christmas campaign, which has a powerful message: a person's story is made up of shared moments that will be remembered at the very end.
  • Ruavieja then captured the moment when they watched the film, as well as their reactions, reminding us of the importance of spending time with the people we love.
  • The campaign takes the spirit of the iconic 2018 " We have to see more of each other " campaign and ends with the same slogan, reminding us to prioritise what really matters in life.

Veterinarians, Veterinary Cardiologists and Animal Nutritionists Found Grain-Free Diets Had No Negative Impact on Heart Health of Dogs and Did Not Lead to DCM

Retrieved on: 
Tuesday, October 10, 2023
Multimedia, Heart, VTS, Doctor of Philosophy, Diet, Frontiers Media, University of Missouri College of Agriculture, Food and Natural Resources, University, Pea, ACAS, Veterinarian, CFS, Cardiology, Associate, Dog, Dilated cardiomyopathy, DCM, CVT, PAS, Nutrition, Research, Medical device, Animal feed

The research appeared in a peer-reviewed article in Frontiers in Animal Science .

Key Points: 
  • The research appeared in a peer-reviewed article in Frontiers in Animal Science .
  • "To identify any changes in cardiac function over time, our multi-disciplinary team collected and examined a wide cross-section of data."
  • Two diets were grain-free, contained pulse ingredients (peas and lentils) and potatoes, and included either low or high amounts of animal protein.
  • Two diets were grain-inclusive, contained no pulse ingredients or potatoes, and included either low or high amounts of animal protein.

248 leading scientists warn of Harmful Health Effects of Blue-Rich LED Light at Night

Retrieved on: 
Monday, October 9, 2023
Consensus, Health, Obesity, Breast cancer, Risk, Scientific consensus, Diabetes, Sleep, Frontiers Media, Light, Harvard Medical School, Light-emitting diode, Dietary supplement

BOSTON, Oct. 9, 2023 /PRNewswire/ -- Many of the lights sold today are causing major health problems, including obesity, diabetes, and breast cancer. Why? They are blue-enriched LEDs, which play havoc on people's circadian rhythms during the evening hours. On October 10th, Blue Light Awareness Day, the Circadian Light Research Center announces the publication in Frontiers in Photonics of a consensus survey which confirms that human circadian clocks are highly sensitive to blue wavelengths, and insufficient daytime blue-rich light and excessive blue-rich light at night, leads to many health disorders.

Key Points: 
  • BOSTON, Oct. 9, 2023 /PRNewswire/ -- Many of the lights sold today are causing major health problems, including obesity, diabetes, and breast cancer.
  • People should purchase lights for evening and night use that do not contain blue light and use blue-enriched LEDs during daytime only."
  • 248 scientists, with a total of 2,697 peer-reviewed publications on light and circadian clocks since 2008, completed a survey with potential consensus statements.
  • There is now sufficient evidence to support the widespread introduction of circadian lighting that adjusts light intensity and blue content across day and night to maintain robust circadian entrainment and health.

AKC Canine Health Foundation Celebrates 1,000th Scientific Publication

Retrieved on: 
Thursday, July 20, 2023
Science, Partnership, Dog, Veterinarian, Veterinary medicine, Organization, Frontiers Media, Health, Ageing, Research, Infection, Doctor of Philosophy, North Carolina State University, Thought, Pain, Journal of Veterinary Internal Medicine, Journal, Publication, AKC, CHF, Behavior, Vaccine, Pharmaceutical industry

RALEIGH, N.C., July 20, 2023 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health and well-being of all dogs, proudly announces the publication of its 1,000th scientific study. This significant milestone demonstrates CHF's unwavering commitment to improving the lives of dogs.

Key Points: 
  • Non-Profit Organization Drives Groundbreaking Canine Health Research, Advancing the Health of Dogs
    RALEIGH, N.C., July 20, 2023 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health and well-being of all dogs, proudly announces the publication of its 1,000th scientific study.
  • Dr. Stephanie Montgomery, CHF Chief Executive Officer, emphasizes the profound impact of the Foundation's funding, stating, "The AKC Canine Health Foundation has left an indelible mark on the health and well-being of dogs worldwide.
  • With an ongoing portfolio of 158 active canine health research studies, CHF supports research that advances the health of dogs.
  • To be awarded funding, all projects undergo evaluation of scientific merit and the potential to advance canine health by a panel of experts.

New Research Shows Simufilam Suppresses Overactive mTOR

Retrieved on: 
Tuesday, June 27, 2023
Cassava, Cassava Sciences, Research, Doctor of Philosophy, Hyperkinesia, Alzheimer's disease, Frontiers Media, Journal, Patient, Blood, Lymphocyte, Creative Commons license, Pharmaceutical industry, Ageing, Insulin

Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.

Key Points: 
  • Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.
  • “Today’s publication suggests a meaningful impact of simufilam on overactive mTOR signaling,” said Lindsay Burns, PhD, SVP Neuroscience at Cassava Sciences, and co-author of the paper.
  • The research published today shows mTOR is overactive in lymphocytes isolated from blood collected from Alzheimer's patients versus healthy controls.
  • “There is a wide body of research on this topic.”
    An abstract of the research paper appeared on-line June 23, 2023, ahead of print and is titled “Simufilam Suppresses Overactive mTOR and Restores Its Sensitivity to Insulin in Alzheimer’s Disease Patient Lymphocytes”.